Drug intelligence / Profile preview

TVD3-001

Development stage: Unknown
Lead developer: eptivA Therapeutics
Modality: Small Molecules
Administration: Transdermal

Overview

TVD3-001 is a transdermal patch formulation of cholecalciferol (vitamin D3) being developed by eptivA Therapeutics, under license from To Better Days, for the treatment of chronic pain. Cholecalciferol acts as an agonist of the Vitamin D receptor (VDR), which is hypothesized to modulate nociceptive pathways and suppress hyperactivity in transient receptor potential vanilloid 1 (TRPV1) pain receptors. Originally developed as an over-the-counter wellness patch by To Better Days, the formulation is being advanced through Phase I/II clinical development for prescription indications in pain management.

Brand names: To Better Days
Other names: cholecalciferol patchtransdermal cholecalciferol patchtransdermal vitamin D3 patchvitamin D3 patch

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on TVD3-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TVD3-001.

Explore the full profile